Gpth.Ns
GPTH.NS operates in the healthcare sector, primarily engaged in pharmaceuticals, and generates revenue through the provision of healthcare services and equipment.
Business. GPTH.NS operates in the healthcare sector, primarily engaged in pharmaceuticals, and generates revenue through the provision of healthcare services and equipment.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
GPTH.NS operates in the healthcare sector, primarily engaged in pharmaceuticals, and generates revenue through the provision of healthcare services and equipment.
GPTH.NS maintains a conservative capital structure with a debt-to-equity ratio of 0.14, indicating a low reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 1.06, suggesting a balanced approach to managing short-term obligations. The company's return on equity of 20.14% and return on assets of 12.99% reflect strong profitability relative to its equity and asset base.
The company's profitability is further underscored by a gross profit margin of 80.64% and an operating margin of 16.29%, both of which are indicative of efficient cost management and pricing power. These metrics align with the industry's preferred focus on gross and operating margins, suggesting that GPTH.NS is performing in line with or above the median for its sector.
Geographically and segment-wise, the company's revenue concentration is not explicitly detailed in the available data, but the absence of disclosed segment or geographic breakdowns implies a potentially diversified or consolidated business model. This lack of segmentation data limits the ability to assess specific growth drivers or regional vulnerabilities.
The company's growth trajectory is supported by a positive free cash flow of 190.26 million INR, which provides flexibility for reinvestment or shareholder returns. Analysts have assigned a mean price target of 136.00 INR, with a single buy recommendation, indicating a generally positive outlook for the company's stock.
Risk factors for GPTH.NS include a medium liquidity risk, as evidenced by a current ratio just above 1, and a note that net cash is negative after subtracting total debt. The dilution risk is assessed as low, with no significant dilution potential identified in the basic shares outstanding.
Recent events and filings have not been detailed in the provided data, but the company's financial snapshot and analyst estimates suggest a stable and potentially growing business.
- GPTH.NS demonstrates strong profitability with a high return on equity and operating margin.
- The company's capital structure is conservative, with a low debt-to-equity ratio.
- Analysts have a generally positive outlook, with a mean price target of 136.00 INR.
- The company's liquidity position is moderate, with a current ratio of 1.06.
- There is a low risk of dilution, as indicated by the low dilution score.
- margin_outlook_rationale: The company's gross and operating margins are strong, indicating efficient operations and pricing power.
- rd_outlook_rationale: No specific R&D outlook is provided, but the company's profitability suggests ongoing investment in innovation.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 4,60 |
| Revenue | —no estimate | —no estimate | 4,7B INR |
| Operating income | —no estimate | —no estimate | 566,0M INR |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- GPTH.NS Market data — financials · 2026-05-28
- GPT Healthcare Ltd Market data — analyst estimates · 2026-05-28